Literature DB >> 18000990

Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.

Mirjam B Zeisel1, George Koutsoudakis, Eva K Schnober, Anita Haberstroh, Hubert E Blum, François-Loïc Cosset, Takaji Wakita, Daniel Jaeck, Michel Doffoel, Cathy Royer, Eric Soulier, Evelyne Schvoerer, Catherine Schuster, Françoise Stoll-Keller, Ralf Bartenschlager, Thomas Pietschmann, Heidi Barth, Thomas F Baumert.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Scavenger receptor class B type I (SR-BI) has been shown to bind HCV envelope glycoprotein E2, participate in entry of HCV pseudotype particles, and modulate HCV infection. However, the functional role of SR-BI for productive HCV infection remains unclear. In this study, we investigated the role of SR-BI as an entry factor for infection of human hepatoma cells using cell culture-derived HCV (HCVcc). Anti-SR-BI antibodies directed against epitopes of the human SR-BI extracellular loop specifically inhibited HCVcc infection in a dose-dependent manner. Down-regulation of SR-BI expression by SR-BI-specific short interfering RNAs (siRNAs) markedly reduced the susceptibility of human hepatoma cells to HCVcc infection. Kinetic studies demonstrated that SR-BI acts predominately after binding of HCV at an entry step occurring at a similar time point as CD81-HCV interaction. Although the addition of high-density lipoprotein (HDL) enhanced the efficiency of HCVcc infection, anti-SR-BI antibodies and SR-BI-specific siRNA efficiently inhibited HCV infection independent of lipoprotein.
CONCLUSION: Our data suggest that SR-BI (i) represents a key host factor for HCV entry, (ii) is implicated in the same HCV entry pathway as CD81, and (iii) targets an entry step closely linked to HCV-CD81 interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000990     DOI: 10.1002/hep.21994

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  119 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

3.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

4.  Hepatitis C virus replication and potential targets for direct-acting agents.

Authors:  Jacqueline G O'Leary; Gary L Davis
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

5.  Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate.

Authors:  Jieyun Jiang; Wei Cun; Xianfang Wu; Qing Shi; Hengli Tang; Guangxiang Luo
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

6.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

7.  Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.

Authors:  Hua Liang; Rodney S Russell; Nicole L Yonkers; David McDonald; Benigno Rodriguez; Clifford V Harding; Donald D Anthony
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

9.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

Review 10.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.